Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Multi-Center Benchmarking of a Commercially Available Artificial Intelligence Algorithm for Prostate Imaging Reporting and Data System (PI-RADS) Score Assignment and Lesion Detection in Prostate MRI
4
Zitationen
17
Autoren
2025
Jahr
Abstract
BACKGROUND: The increase in multiparametric magnetic resonance imaging (mpMRI) examinations as a fundamental tool in prostate cancer (PCa) diagnostics raises the need for supportive computer-aided imaging analysis. Therefore, we evaluated the performance of a commercially available AI-based algorithm for prostate cancer detection and classification in a multi-center setting. METHODS: Representative patients with 3T mpMRI between 2017 and 2022 at three different university hospitals were selected. Exams were read according to the PI-RADSv2.1 protocol and then assessed by an AI algorithm. Diagnostic accuracy for PCa of both human and AI readings were calculated using MR-guided ultrasound fusion biopsy as the gold standard. RESULTS: Analysis of 91 patients resulted in 138 target lesions. Median patient age was 67 years (range: 49-82), median PSA at the time of the MRI exam was 8.4 ng/mL (range: 1.47-73.7). Sensitivity and specificity for clinically significant prostate cancer (csPCa, defined as ISUP ≥ 2) were 92%/64% for radiologists vs. 91%/57% for AI detection on patient level and 90%/70% vs. 81%/78% on lesion level, respectively (cut-off PI-RADS ≥ 4). Two cases of csPCa were missed by the AI on patient-level, resulting in a negative predictive value (NPV) of 0.88 at a cut-off of PI-RADS ≥ 3. CONCLUSIONS: AI-augmented lesion detection and scoring proved to be a robust tool in a multi-center setting with sensitivity comparable to the radiologists, even outperforming human reader specificity on both patient and lesion levels at a threshold of PI-RADS ≥3 and a threshold of PI-RADS ≥ 4 on lesion level. In anticipation of refinements of the algorithm and upon further validation, AI-detection could be implemented in the clinical workflow prior to human reading to exclude PCa, thereby drastically improving reading efficiency.
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.713 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.473 Zit.
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
2006 · 5.258 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.560 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.506 Zit.